Merck Serono: Data on Safinamide to Be Presented at the 14th MDS Meeting

GENEVA, June 10, 2010 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
and its partner Newron Pharmaceuticals S.p.A., today announced that new data
on safinamide will be presented at the 14th annual meeting of the Movement
Disorder Society (MDS), an international congress of Parkinson's disease and
movement disorders taking place June 13 to 17, in Buenos Aires, Argentina.
Safinamide is an investigational oral therapy being assessed in Phase III
trials as add-on treatment to dopamine agonist or levodopa in early to late
stage Parkinson's disease (PD).

"The results presented at the 14th MDS congress will
contribute to improve the understanding of the mechanism of action of
safinamide," said Bernhard Kirschbaum, Merck Serono's Head of Global Research
and Development. "We believe that safinamide has the potential to become one
of the first add-on therapies to treat early to late stage Parkinson's
disease."

The following abstracts have been accepted for the poster presentation at
the 14th MDS annual meeting:

Poster presentations

    - Safinamide reduces levodopa-induced dyskinesia in
      MPTP-lesioned primates while prolonging anti-parkinsonian efficacy

      (Poster 680, June 16, 2010, 1:30-3 p.m. local time; Guided
      Poster Tour 2, June 14, 2010: 2-3:30 p.m. local time)

    - MOTION (safinaMide add-On To dopamine agonist in early
      Idiopathic ParkinsON's disease) study design: a 24-week,
      double-blind, placebo-controlled study of the efficacy and safety of
      safinamide

      (Poster 319, June 15, 2010, 1:30-3 p.m. local time)

    - Effect of safinamide on depressive symptoms in patients with
      mid-late stage Parkinson's disease

     (Poster 324, June 15, 2010, 1:30-3 p.m. local time)

    - Safinamide as add-on to levodopa improves motor function
      without worsening dyskinesia in patients with mid-late Parkinson's
      disease 

      (Poster 359, June 15, 2010, 1:30-3 p.m. local time; Guided
      Poster Tour 13, June 17, 2010, 1:30-3 p.m. local time)

    - SETTLE study design: a 24-week, double-blind,
      placebo-controlled study of the efficacy and safety of safinamide as
      add-on therapy to levodopa in patients with Parkinson's disease

      (Poster 378, June 15 2010, 1:30-3 p.m. local time)

    - Cognitive deficits in patients with mid- to late-stage
      Parkinson's disease

      (Poster 404, June 15, 2010, 1:30-3 p.m. local time)

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central
nervous system that often impairs the patient's motor skills and speech.
Parkinson's disease belongs to a group of conditions called movement
disorders. It is characterized by muscle rigidity, tremor, a slowing of
physical movement (bradykinesia) and, in extreme cases, a loss of physical
movement (akinesia). The primary symptoms are the results of decreased
stimulation of the motor cortex by the basal ganglia, normally caused by the
insufficient formation and action of dopamine, which is produced in the
dopaminergic neurons of the brain. Secondary symptoms may include high-level
cognitive dysfunction and subtle language problems. Parkinson's disease is
both chronic and progressive. It is estimated that more than 3 million people
in the industrialized countries suffer from Parkinson's disease.

About Merck Serono

Merck Serono is the division for innovative prescription
pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical
and chemical company. Headquartered in Geneva, Switzerland, Merck Serono
discovers, develops, manufactures and markets innovative small molecules and
biopharmaceuticals to help patients with unmet medical needs. In the United
States and Canada, EMD Serono operates through separately incorporated
affiliates.

Merck Serono has leading brands serving patients with cancer (Erbitux(R),
cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility
(Gonal-f(R), follitropin alfa), endocrine and metabolic disorders (Saizen(R)
and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well
as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R),
bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in
all markets.

With an annual R&D expenditure of more than EUR 1 billion,
Merck Serono is committed to growing its business in specialist-focused
therapeutic areas including neurodegenerative diseases, oncology, fertility
and endocrinology, as well as new areas potentially arising out of research
and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with
total revenues of EUR 7.7 billion in 2009, a history that began in 1668, and
a future shaped by approximately 33,600 employees in 64 countries. Its
success is characterized by innovations from entrepreneurial employees.
Merck's operating activities come under the umbrella of Merck KGaA, in which
the Merck family holds an approximately 70% interest and free shareholders
own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co.
was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com
or www.merck.de

Merck Serono S.A. - Geneva, 9 Chemin des Mines, 1202 Genève, Suisse, Media relations,Tel: +41-22-414-36-00